Verastem Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Verastem has been growing earnings at an average annual rate of 9.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 43.4% per year.
Anahtar bilgiler
9.4%
Kazanç büyüme oranı
41.2%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | -43.4% |
Özkaynak getirisi | -223.7% |
Net Marj | -894.9% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade
May 26Verastem: Moving Forward
Sep 13Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?
Sep 01Verastem Non-GAAP EPS of -$0.11 in-line
Aug 08Verastem: Looking Increasingly Attractive
Jun 29Verastem: Time To Take My Position Out Of Mothball
Apr 19Vectoring In On Verastem
Jan 12Verastem: Buying Opportunity Following Unjustified Sell-Off
Sep 22Gelir ve Gider Dağılımı
Verastem nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 10 | -89 | 37 | 72 |
31 Mar 24 | 0 | -106 | 34 | 67 |
31 Dec 23 | 0 | -87 | 31 | 61 |
30 Sep 23 | 0 | -77 | 28 | 50 |
30 Jun 23 | 0 | -75 | 27 | 47 |
31 Mar 23 | 0 | -73 | 26 | 49 |
31 Dec 22 | 3 | -74 | 25 | 51 |
30 Sep 22 | 3 | -73 | 25 | 51 |
30 Jun 22 | 3 | -78 | 24 | 49 |
31 Mar 22 | 4 | -73 | 24 | 44 |
31 Dec 21 | 2 | -71 | 24 | 39 |
30 Sep 21 | 2 | -75 | 26 | 38 |
30 Jun 21 | 81 | -39 | 38 | 40 |
31 Mar 21 | 84 | -45 | 47 | 39 |
31 Dec 20 | 89 | -68 | 59 | 41 |
30 Sep 20 | 92 | -87 | 75 | 43 |
30 Jun 20 | 22 | -130 | 80 | 45 |
31 Mar 20 | 21 | -149 | 93 | 46 |
31 Dec 19 | 17 | -149 | 101 | 46 |
30 Sep 19 | 15 | -122 | 104 | 42 |
30 Jun 19 | 22 | -113 | 107 | 41 |
31 Mar 19 | 28 | -89 | 93 | 42 |
31 Dec 18 | 27 | -72 | 77 | 44 |
30 Sep 18 | 26 | -79 | 58 | 46 |
30 Jun 18 | 10 | -81 | 38 | 52 |
31 Mar 18 | 0 | -76 | 26 | 49 |
31 Dec 17 | 0 | -68 | 21 | 46 |
30 Sep 17 | 0 | -61 | 19 | 42 |
30 Jun 17 | 0 | -46 | 18 | 29 |
31 Mar 17 | 0 | -41 | 18 | 24 |
31 Dec 16 | 0 | -36 | 17 | 20 |
30 Sep 16 | 0 | -37 | 17 | 21 |
30 Jun 16 | 0 | -44 | 17 | 28 |
31 Mar 16 | 0 | -51 | 17 | 34 |
31 Dec 15 | 0 | -58 | 18 | 41 |
30 Sep 15 | 0 | -60 | 18 | 43 |
30 Jun 15 | 0 | -58 | 18 | 40 |
31 Mar 15 | 0 | -55 | 18 | 38 |
31 Dec 14 | 0 | -53 | 18 | 35 |
30 Sep 14 | 0 | -51 | 17 | 34 |
30 Jun 14 | 0 | -48 | 17 | 31 |
31 Mar 14 | 0 | -45 | 16 | 29 |
Kaliteli Kazançlar: VSTM is currently unprofitable.
Büyüyen Kar Marjı: VSTM is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: VSTM is unprofitable, but has reduced losses over the past 5 years at a rate of 9.4% per year.
Büyüme Hızlandırma: Unable to compare VSTM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: VSTM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: VSTM has a negative Return on Equity (-223.67%), as it is currently unprofitable.